You have 9 free searches left this month | for more free features.

Myelodysplastic Syndrome

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Luspatercept in Korean Myelodysplastic Syndrome or ß-thalassemia

Not yet recruiting
  • Myelodysplastic Syndrome
  • Beta Thalassemia
  • Seoul, Korea, Republic of
    Bristol-Myers Squibb YH
Oct 3, 2023

Samples of Bone Marrow Aspiration From Myelodysplastic Syndrome

Recruiting
  • Myelodysplastic Syndromes
  • Blood test
  • Jerusalem, Israel
    Shaare Zedek Medical Center
Nov 27, 2023

MDS, Myelodysplastic Anemia, Myelodysplastic Syndrome With Isolated Del(5Q) Trial (description of MDS pzatient cohort)

Recruiting
  • Myelodysplastic Syndromes
  • +5 more
  • description of MDS pzatient cohort
  • Brest, France
    Chu Brest
Oct 27, 2022

Acute Myeloid Leukemia, MDS Trial (idarubicin, Cytarabine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • (no location specified)
Sep 18, 2023

Haplo-HSCT for Elderly Acute Leukemia/ Myelodysplastic Syndrome

Not yet recruiting
  • Acute Leukemia
  • Myelodysplastic Syndromes
    • Beijing, Beijing, China
      Peking University People's Hospital
    Jun 5, 2023

    Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome Trial in Scottsdale, Cleveland,

    Completed
    • Chronic Myelomonocytic Leukemia
    • +3 more
    • Scottsdale, Arizona
    • +3 more
    Jan 12, 2023

    Acute Myeloid Leukemia, High-Risk and Very High-Risk MDS Trial (SGR-2921)

    Not yet recruiting
    • Acute Myeloid Leukemia
    • High-Risk and Very High-Risk Myelodysplastic Syndromes
    • (no location specified)
    Jul 25, 2023

    Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 Trial in Boston (BXCL701)

    Not yet recruiting
    • Acute Myeloid Leukemia
    • Myelodysplastic Syndrome With Excess Blasts-2
    • Boston, Massachusetts
      Dana Farber Cancer Institute
    Jan 26, 2023

    Myelodysplastic Syndrome Trial in Nagoya, Fukuoka, Tokyo (SyB L-1101)

    Completed
    • Myelodysplastic Syndrome
    • SyB L-1101
    • Nagoya, Aichi, Japan
    • +2 more
    Nov 14, 2022

    Secondary Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome Trial in Columbus (Azacitidine, Quality-of-Life

    Recruiting
    • Secondary Myelodysplastic Syndrome
    • Therapy-Related Myelodysplastic Syndrome
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Dec 1, 2022

    MDS, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic Trial in Newcastle (Subcutaneous azacitidine, Oral

    Not yet recruiting
    • Myelodysplastic Syndromes
    • +3 more
    • Subcutaneous azacitidine
    • Oral decitabine/cedazuridine
    • Newcastle, New South Wales, Australia
      Calvary Mater Newcastle
    May 29, 2023

    Myelodysplastic Syndrome Trial in Japan (SyB C-1101 and Azacytidine)

    Withdrawn
    • Myelodysplastic Syndrome
    • SyB C-1101 and Azacytidine
    • Nagoya, Aichi, Japan
    • +3 more
    Nov 14, 2022

    Myelodysplastic Syndrome Trial in Japan (SyB C-1101)

    Completed
    • Myelodysplastic Syndrome
    • SyB C-1101
    • Nagoya, Aichi, Japan
    • +3 more
    Nov 14, 2022

    Acute Myeloid Leukemia and Myelodysplastic Syndrome Trial in Tianjin (QLF32101)

    Not yet recruiting
    • Acute Myeloid Leukemia and Myelodysplastic Syndrome
    • Tianjin, Tianjin, China
      Institute of Hematology&Blood Diseases Hospital,Chinese Academy
    Jan 27, 2023

    MDS Trial in Seoul (cyclophosphamide, fludarabine, and antithymocyte globulin)

    Active, not recruiting
    • Myelodysplastic Syndromes
    • cyclophosphamide, fludarabine, and antithymocyte globulin
    • Seoul, Korea, Republic of
      Asan Medical Center, University of Ulsan College of Medicine
    Oct 19, 2023

    Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial (UAE Inhibitor TAK-243)

    Not yet recruiting
    • Myelodysplastic Syndrome
    • +4 more
    • UAE Inhibitor TAK-243
    • (no location specified)
    Oct 20, 2022

    Myelodysplastic Syndrome Trial in Japan (SyB C-1101)

    Completed
    • Myelodysplastic Syndrome
    • SyB C-1101
    • Nagoya, Aichi, Japan
    • +8 more
    Nov 14, 2022

    MDS Trial (Yisui granule, Placebo)

    Not yet recruiting
    • MDS
    • Yisui granule
    • Placebo
    • (no location specified)
    Jan 13, 2023

    Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia Trial in Houston (Decitabine, Quizartinib,

    Recruiting
    • Acute Myeloid Leukemia
    • +4 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 27, 2023

    Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2 Trial in Houston

    Active, not recruiting
    • Chronic Myelomonocytic Leukemia-0
    • +5 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 18, 2023

    Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia Trial in Houston

    Recruiting
    • Chronic Myelomonocytic Leukemia
    • +5 more
    • Canakinumab
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 7, 2022

    High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston

    Completed
    • High Risk Myelodysplastic Syndrome
    • +2 more
    • Daratumumab
    • Houston, Texas
      M D Anderson Cancer Center
    Nov 21, 2022

    Clonal Cytopenia of Undetermined Significance, Essential Thrombocythemia, Myelodysplastic Syndrome Trial in Los Angeles

    Not yet recruiting
    • Clonal Cytopenia of Undetermined Significance
    • +4 more
    • Biospecimen Collection
    • +6 more
    • Los Angeles, California
    • +1 more
    Oct 4, 2023

    Higher Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia Trial (AMG 176, Azacitidine)

    Not yet recruiting
    • Higher Risk Myelodysplastic Syndrome
    • Chronic Myelomonocytic Leukemia
    • (no location specified)
    Jul 29, 2022

    Hematopoietic and Lymphoid Cell Tumor, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia Trial in Houston

    Recruiting
    • Hematopoietic and Lymphoid Cell Neoplasm
    • +6 more
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 31, 2022